Drugs / Busulfan
last change 3 days ago re-read 2 minutes ago

Busulfan

Small molecule

Developed for
myelodysplastic syndrome · leukemia · plasma cell myeloma · acute myeloid leukemia · lymphoma · disease related to hematopoietic stem cell transplant · acute lymphoblastic leukemia · chronic myeloid leukemia
+169 more · myelodysplastic/myeloproliferative disease · plasma cell neoplasm · neuroblastoma · myeloproliferative neoplasm · Hodgkins lymphoma · childhood acute myeloid leukemia · non-Hodgkin lymphoma · acute myeloid leukemia with 11q23 abnormalities · chronic lymphocytic leukemia/small lymphocytic lymphoma · hematopoietic and lymphoid cell neoplasm · acute myeloid leukemia with t(8;21)(q22;q22) translocation · immunodeficiency disease · myelofibrosis · aplastic anemia · acute myeloid leukemia, t(16;16)(p13.1;q22) · Ewing sarcoma · sickle cell disease · acute leukemia · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · bone marrow failure syndrome · Burkitt lymphoma · central nervous system neoplasm · childhood myelodysplastic syndrome · graft versus host disease · peripheral T-cell lymphoma, not otherwise specified · primary central nervous system lymphoma · acute myeloid leukemia, del(5q31-q32) · anemia · cancer of unknown primary site · childhood malignant neoplasm · chronic myelomonocytic leukemia · Diamond-Blackfan anemia · extranodal nasal NK/T cell lymphoma · Fanconi anemia · juvenile myelomonocytic leukemia · lymphoproliferative syndrome · mantle cell lymphoma · myeloid leukemia · sarcoma · severe congenital neutropenia · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myeloid leukemia, inv(16)(p13.1;q22) · acute myelomonocytic leukemia M4 · adult acute monocytic leukemia · anaplastic large cell lymphoma · Chediak-Higashi syndrome · chronic granulomatous disease · grade III lymphomatoid granulomatosis · hematologic disorder · hepatosplenic T-cell lymphoma · intraocular lymphoma · large-cell immunoblastic lymphoma · MALT lymphoma · myelodysplastic/myeloproliferative neoplasm · nodal marginal zone B-cell lymphoma · plasma cell leukemia · severe combined immunodeficiency · splenic marginal zone lymphoma · supratentorial primitive neuroectodermal tumor · T-cell non-Hodgkin lymphoma · testicular lymphoma · Waldenstrom macroglobulinemia · Wiskott-Aldrich syndrome · X-linked lymphoproliferative syndrome · acquired polycythemia vera · acute myeloid leukemia with multilineage dysplasia · acute promyelocytic leukemia · adult acute lymphoblastic leukemia · adult T-cell leukemia/lymphoma · angioimmunoblastic T-cell lymphoma · beta thalassemia · beta-thalassemia major · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · breast cancer · cancer · childhood acute lymphoblastic leukemia · childhood acute megakaryoblastic leukemia · congenital amegakaryocytic thrombocytopenia · diffuse large B-cell lymphoma · follicular lymphoma · ganglioneuroblastoma · Griscelli syndrome · kidney cancer · Langerhans cell histiocytosis · leukemia, myeloid, accelerated-phase · lymphoid neoplasm · malignant testicular germ cell tumor · mycosis fungoides and variants · myelodysplastic syndrome associated with isolated del(5q) · myelodysplastic syndrome with excess blasts · myeloid neoplasm · myeloproliferative neoplasm, unclassifiable · paroxysmal nocturnal hemoglobinuria · primary cutaneous B-cell lymphoma · primary myelofibrosis · retinoblastoma · rhabdomyosarcoma · Shwachman-Diamond syndrome · small intestine lymphoma · T-cell immunodeficiency · T-cell large granular lymphocyte leukemia · thalassemia · therapy related acute myeloid leukemia and myelodysplastic syndrome · acute biphenotypic leukemia · acute erythroid leukemia · acute leukemia of ambiguous lineage · acute myeloid leukemia, FLT3 internal tandem duplication · acute myeloid leukemia, inv(3)(q21.3;q26.2) · acute myeloid leukemia, t(15;17)(q24;q21) · acute myeloid leukemia, t(6;9)(p23;q34.1) · adult central nervous system germ cell tumor · atypical chronic myeloid leukemia, BCR-ABL1 negative · B-cell acute lymphoblastic leukemia · B-cell chronic lymphocytic leukemia · benign neoplasm · central nervous system cancer · central nervous system non-hodgkin lymphoma · childhood brain stem glioma · childhood central nervous system germ cell tumor · childhood cerebellar astrocytic neoplasm · childhood cerebral astrocytoma · childhood ependymoma · childhood germ cell tumor · childhood medulloblastoma · disease of genetic or genomic mechanism · engraftment syndrome · essential thrombocythemia · Ewing sarcoma of bone · extragonadal nonseminomatous germ cell tumor · extraskeletal Ewing sarcoma · hairy cell leukemia · hemoglobinopathy · hepatoblastoma · high grade B-cell lymphoma · histiocytosis · immune dysregulation, autoimmunity, and autoinflammation · inborn errors of metabolism · inflammatory breast carcinoma · kidney neoplasm · lymphoblastic lymphoma · lymphoid hemopathy · lymphoid leukemia · lymphoplasmacytic lymphoma · malignant childhood germ cell neoplasm · marginal zone lymphoma · mature T-cell and NK-cell non-Hodgkin lymphoma · metabolic disease · metastatic malignant neoplasm · mixed phenotype acute leukemia · optic pathway glioma · ovarian mixed germ cell neoplasm · pineoblastoma · post-transplant lymphoproliferative disease · primary cutaneous T-cell non-Hodgkin lymphoma · prolymphocytic leukemia · refractory malignant neoplasm · sickle cell-hemoglobin c disease syndrome · systemic lupus erythematosus · systemic sclerosis · T lymphoblastic leukemia/lymphoma · T-cell and NK-cell neoplasm · testicular germ cell tumor · triple-negative breast carcinoma · urinary bladder cancer · urothelial carcinoma · Wilms tumor · acute undifferentiated leukemia · T-cell leukemia
Investigated by
National Cancer Institute (NCI) · M.D. Anderson Cancer Center · Fred Hutchinson Cancer Center · Memorial Sloan Kettering Cancer Center · Masonic Cancer Center, University of Minnesota · Peking University People's Hospital
+197 more · City of Hope Medical Center · Seoul National University Hospital · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou First People's Hospital · Institute of Hematology & Blood Diseases Hospital, China · Nanfang Hospital, Southern Medical University · National Heart, Lung, and Blood Institute (NHLBI) · Otsuka Pharmaceutical Development & Commercialization, Inc. · Shanghai Jiao Tong University School of Medicine · University of California, San Francisco · Case Comprehensive Cancer Center · Columbia University · European Organisation for Research and Treatment of Cancer - EORTC · Institut Paoli-Calmettes · Northwestern University · Third Affiliated Hospital, Sun Yat-Sen University · Ann & Robert H Lurie Children's Hospital of Chicago · Celgene Corporation · Children's Oncology Group · First People's Hospital of Chenzhou · H. Lee Moffitt Cancer Center and Research Institute · National Marrow Donor Program · Roswell Park Cancer Institute · Sichuan University · Zhujiang Hospital · Alliance for Clinical Trials in Oncology · Assistance Publique - Hôpitaux de Paris · Center for International Blood and Marrow Transplant Research · Children's Cancer and Leukaemia Group · Children's Hospital Medical Center, Cincinnati · Genzyme, a Sanofi Company · Inje University · Northside Hospital, Inc. · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · The Seventh Affiliated Hospital of Sun Yat-sen University · University of Chicago · University of Michigan Rogel Cancer Center · Amgen · Asan Medical Center · Association for Training, Education, and Research in Hematology, Immunology, and Transplantation · Barbara Ann Karmanos Cancer Institute · Blood and Marrow Transplant Clinical Trials Network · Blood and Marrow Transplant Group of Georgia · California Institute for Regenerative Medicine (CIRM) · Cancer Research UK · Herbert Irving Comprehensive Cancer Center · Institut Curie · Massachusetts General Hospital · Medical College of Wisconsin · National Institute of Allergy and Infectious Diseases (NIAID) · New York Medical College · OHSU Knight Cancer Institute · Otsuka America Pharmaceutical · Otsuka Pharmaceutical Co., Ltd. · Pediatric Brain Tumor Consortium · Samsung Medical Center · Severance Hospital · Societe Francaise Oncologie Pediatrique · Soonchunhyang University Hospital · St. Jude Children's Research Hospital · The First Affiliated Hospital of Soochow University · The Korean Society of Pediatric Hematology Oncology · Ulsan University Hospital · University of Birmingham · University of Illinois at Chicago · University of Leicester · University of Miami · AIDS Malignancy Consortium · ALL SCTped Forum · ALL-BFM Study Group · Abramson Cancer Center at Penn Medicine · Adienne SA · Agence de La Biomédecine · Albert Einstein College of Medicine · all 203 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Busilvex 2003-07-09 europa.eu
Label expansion US (FDA) BUSULFEX 2003-01-13 fda.gov
Approved US (FDA) MYLERAN 1954-06-26 fda.gov

Trials 306 · started per year

today
US approved 1954
EU approved 2003
1
1
1
1
4
3
2
7
9
11
14
7
6
7
9
15
13
18
13
11
13
17
12
12
9
8
13
5
16
5
4
8
8
5
6
5
6
19531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT04776850 Dec 2020 → Dec 2022 beta-thalassemia major, sickle cell disease, sickle cell-beta plus-thalassemia, sickle cell-beta zero-thalassemia M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 0 NCT01959477 Mar 2014 → Jan 2015 Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia +19 Case Comprehensive Cancer Center Completed No outcome recorded
Phase 0 NCT00426517 Jan 2007 → Nov 2019 immunodeficiency disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 124 trials
Phase 1 NCT06809712 Aug 2022 → Oct 2026 expected hematologic disorder He Huang Recruiting No outcome recorded
Phase 1 NCT04098393 Sep 2019 → Sep 2026 expected hematopoietic and lymphoid cell neoplasm Memorial Sloan Kettering Cancer Center Active not recruiting No outcome recorded
Phase 1 NCT03517631 Feb 2018 → Dec 2020 AIDS Shanghai Public Health Clinical Center Unknown No outcome recorded
Phase 1 NCT02512497 Dec 2017 → Oct 2023 T-cell large granular lymphocyte leukemia, T-cell prolymphocytic leukemia, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma Ohio State University Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT02500849 Mar 2016 → Aug 2026 overdue HIV infectious disease City of Hope Medical Center Active not recruiting No outcome recorded
Phase 1 NCT01961063 Dec 2015 → Aug 2026 overdue HIV infectious disease, plasmablastic lymphoma, primary effusion lymphoma City of Hope Medical Center Active not recruiting No outcome recorded
Phase 1 NCT02660281 Oct 2015 → Oct 2019 immunodeficiency disease, myelofibrosis, plasma cell myeloma University of Rochester Completed No outcome recorded
Phase 1 NCT01798004 Apr 2013 → Jul 2015 ganglioneuroblastoma, neuroblastoma Children's Oncology Group Completed No outcome recorded
Phase 1 NCT01969942 Apr 2013 → Oct 2016 Ewing sarcoma University of Louisville Withdrawn No outcome recorded
Phase 1 NCT01471067 Jul 2012 → Apr 2017 disease related to hematopoietic stem cell transplant, leukemia, lymphoma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1/231 trials
Phase 1/2 NCT06158828 Nov 2024 → Sep 2028 expected acute myeloid leukemia by FAB classification, childhood acute myeloid leukemia Washington University School of Medicine Recruiting No outcome recorded
Phase 1/2 NCT03795597 May 2019 → Nov 2022 plasma cell myeloma Loyola University Unknown No outcome recorded
Phase 1/2 NCT01512888 Aug 2016 → Aug 2026 combined immunodeficiency, X-linked St. Jude Children's Research Hospital Suspended No outcome recorded
Phase 1/2 NCT02589145 Jun 2016 → Apr 2019 lymphoma M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 1/2 NCT02701673 Jun 2016 → Jun 2019 lymphoma M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 1/2 NCT02034630 Jul 2014 → Dec 2023 disease of genetic or genomic mechanism Seoul National University Hospital Unknown No outcome recorded
Phase 1/2 NCT02053545 Dec 2013 → May 2017 leukemia, lymphoma, myelodysplastic syndrome Ann & Robert H Lurie Children's Hospital of Chicago Withdrawn No outcome recorded
Phase 1/2 NCT01983969 Nov 2013 → Nov 2017 cancer of unknown primary site, lymphoma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1/2 NCT01983761 Nov 2013 → Mar 2014 Hodgkins lymphoma, disease related to transplantation, leukemia, myelodysplastic syndrome +1 Targazyme, Inc. Unknown No outcome recorded
Phase 1/2 NCT02061800 Jun 2013 → Jul 2026 overdue acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia +1 Diane George Active not recruiting No outcome recorded
Phase 2181 trials
Phase 2 NCT07524530 Jul 2026 → Jun 2033 expected core binding factor acute myeloid leukemia, lymphoma National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT07677306 Jul 2026 → Dec 2027 expected myelodysplastic syndrome Peking University People's Hospital Not yet recruiting No outcome recorded
Phase 2 NCT05565105 Jun 2026 → Jun 2033 expected acute lymphoblastic leukemia, acute myeloid leukemia Guenther Koehne Not yet recruiting No outcome recorded
Phase 2 NCT07085156 Aug 2025 → May 2028 expected myelodysplastic syndrome Ruijin Hospital Not yet recruiting No outcome recorded
Phase 2 NCT06869265 May 2025 → Apr 2028 expected acute myeloid leukemia Peking University People's Hospital Recruiting No outcome recorded
Phase 2 NCT06802315 Feb 2025 → Mar 2030 expected acute myeloid leukemia, leukemia, myeloid, accelerated-phase, myelodysplastic syndrome University of Illinois at Chicago Recruiting No outcome recorded
Phase 2 NCT06769568 Jan 2025 → Sep 2028 expected aplastic anemia, disease related to hematopoietic stem cell transplant Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 2 NCT06816134 Jan 2025 → Jan 2028 expected acute lymphoblastic leukemia, acute myeloid leukemia The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 2 NCT06872333 Nov 2024 → Jun 2030 expected disease related to hematopoietic stem cell transplant, sickle cell disease Masonic Cancer Center, University of Minnesota Recruiting No outcome recorded
Phase 2 NCT05564390 Jun 2024 → May 2029 expected acute myeloid leukemia with multilineage dysplasia, myelodysplastic syndrome, therapy related acute myeloid leukemia and myelodysplastic syndrome National Cancer Institute (NCI) Recruiting No outcome recorded
Show all 181 trials opens the full record — a long page
Phase 2/315 trials
Phase 2/3 NCT07583888 May 2026 → Aug 2027 expected acute myeloid leukemia, disease related to hematopoietic stem cell transplant The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 2/3 NCT05453552 Jul 2022 → Dec 2023 disease related to hematopoietic stem cell transplant, myelodysplastic syndrome Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT05449899 Jul 2022 → Dec 2023 acute myeloid leukemia, disease related to hematopoietic stem cell transplant Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT04708054 Oct 2021 → Dec 2027 expected acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 2/3 NCT04713956 Jan 2021 → Jul 2023 disease related to hematopoietic stem cell transplant, myelodysplastic syndrome Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT04217278 Jan 2020 → May 2026 overdue acute myeloid leukemia, myelodysplastic syndrome University of Birmingham Active not recruiting No outcome recorded
Phase 2/3 NCT03733327 Nov 2018 → Oct 2021 disease related to hematopoietic stem cell transplant, primary central nervous system lymphoma Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT03385096 Jan 2018 → Dec 2020 disease related to hematopoietic stem cell transplant, plasma cell myeloma Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT02671708 Jan 2016 → Feb 2019 acute myeloid leukemia, disease related to hematopoietic stem cell transplant Nanfang Hospital, Southern Medical University Completed No outcome recorded
Phase 2/3 NCT01949129 Apr 2013 → Jun 2025 overdue acute lymphoblastic leukemia St. Anna Children's Cancer Research Recruiting No outcome recorded
Phase 323 trials
Phase 3 NCT06613035 Sep 2024 → Sep 2027 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 3 NCT06830421 Aug 2023 → Aug 2029 expected primary central nervous system lymphoma University Hospital Freiburg Recruiting No outcome recorded
Phase 3 NCT05466318 Jul 2022 → Dec 2025 T-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma Sichuan University Unknown No outcome recorded
Phase 3 NCT04221035 Nov 2019 → Nov 2026 expected neuroblastoma Gustave Roussy, Cancer Campus, Grand Paris Recruiting No outcome recorded
Phase 3 NCT03126916 May 2018 → Sep 2030 expected neuroblastoma, nodular ganglioneuroblastoma Children's Oncology Group Recruiting No outcome recorded
Phase 3 NCT02724163 Apr 2016 → Dec 2031 expected acute myeloid leukemia University of Birmingham Active not recruiting No outcome recorded
Phase 3 NCT02670252 Jan 2016 → Feb 2020 acute lymphoblastic leukemia, disease related to hematopoietic stem cell transplant Nanfang Hospital, Southern Medical University Completed No outcome recorded
Phase 3 NCT01471444 Nov 2011 → Dec 2020 disease related to hematopoietic stem cell transplant, leukemia M.D. Anderson Cancer Center Completed No outcome recorded
Phase 3 NCT01413178 Sep 2011 → Mar 2019 plasma cell myeloma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 3 NCT01339910 Jun 2011 → Jan 2017 acute myeloid leukemia Medical College of Wisconsin Terminated No outcome recorded
Phase 44 trials
Phase 4 NCT06069180 Nov 2023 → Dec 2024 aplastic anemia Peking University People's Hospital Unknown No outcome recorded
Phase 4 NCT01339988 Jun 2011 → Jun 2014 acute leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome Tel-Aviv Sourasky Medical Center Unknown No outcome recorded
Phase 4 NCT01071486 Aug 2009 → Oct 2012 Rambam Health Care Campus Withdrawn No outcome recorded
Phase 4 NCT00361140 Aug 2005 → Feb 2012 lymphoid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell myeloma H. Lee Moffitt Cancer Center and Research Institute Completed No outcome recorded
Phase not applicable25 trials
NCT07644481 Jul 2026 → Dec 2029 expected acute myeloid leukemia, disease related to hematopoietic stem cell transplant Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
NCT07588594 Feb 2026 → May 2028 expected chronic myelomonocytic leukemia Peking University People's Hospital Recruiting No outcome recorded
NCT06758726 Dec 2024 → Oct 2026 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
NCT06385808 May 2024 → Dec 2026 expected acute myeloid leukemia First Affiliated Hospital Xi'an Jiaotong University Not yet recruiting No outcome recorded
NCT03821987 Dec 2018 → Dec 2021 aplastic anemia, engraftment syndrome Peking University People's Hospital Unknown No outcome recorded
NCT03035422 Jan 2018 → Dec 2021 acute myeloid leukemia Association for Training, Education, and Research in Hematology, Immunology, and Transplantation Completed No outcome recorded
NCT03079089 Jun 2017 → Sep 2023 lymphoid hemopathy Association for Training, Education, and Research in Hematology, Immunology, and Transplantation Completed No outcome recorded
NCT02551718 Sep 2015 → Jun 2020 acute leukemia of ambiguous lineage, acute lymphoblastic leukemia University of Washington Completed No outcome recorded
NCT02179359 Sep 2014 → Nov 2024 Diamond-Blackfan anemia, Glanzmann thrombasthenia, Shwachman-Diamond syndrome, paroxysmal nocturnal hemoglobinuria +3 Masonic Cancer Center, University of Minnesota Terminated No outcome recorded
NCT01795430 Jul 2013 → Mar 2018 Ewing sarcoma of bone, extraskeletal Ewing sarcoma, supratentorial primitive neuroectodermal tumor City of Hope Medical Center Withdrawn No outcome recorded
Also used as a comparator or background therapy in 304 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT03910452 Background Oct 2019 → Jun 2034 expected chronic granulomatous disease National Institute of Allergy and Infectious Diseases (NIAID) Active not recruiting No outcome recorded
Phase 0 NCT00881556 Background Aug 2009 → Sep 2015 epidermolysis bullosa Columbia University Terminated No outcome recorded
Phase 141 trials
Phase 1 NCT07565220 Background Aug 2026 → Jun 2029 expected acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome Sawa Ito, MD Recruiting No outcome recorded
Phase 1 NCT06996119 Background Jun 2026 → May 2027 expected acute myeloid leukemia, graft versus host disease, myelodysplastic syndrome City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT06506461 Background Mar 2025 → Dec 2029 expected sickle cell disease St. Jude Children's Research Hospital Recruiting No outcome recorded
Phase 1 NCT06900192 Background Mar 2025 → Aug 2029 expected primary progressive multiple sclerosis, secondary progressive multiple sclerosis Stanford University Not yet recruiting No outcome recorded
Phase 1 NCT05569512 Background Oct 2022 → Oct 2023 acute myeloid leukemia, childhood malignant neoplasm Malika Kapadia Terminated No outcome recorded
Phase 1/245 trials
Phase 1/2 NCT04370795 Comparator Nov 2025 severe combined immunodeficiency National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase 1/2 NCT07113743 Background Sep 2025 → Sep 2028 expected granulomatous disease, chronic, X-linked National Institute of Allergy and Infectious Diseases (NIAID) Enrolling by invitation No outcome recorded
Phase 1/2 NCT06959771 Background Jul 2025 → Oct 2027 expected hyper-IgM syndrome type 1 National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 1/2 NCT06851767 Background May 2025 → Dec 2034 expected T-B+ severe combined immunodeficiency due to gamma chain deficiency National Institute of Allergy and Infectious Diseases (NIAID) Enrolling by invitation No outcome recorded
Phase 1/2 NCT06325709 Background Apr 2024 → Dec 2032 expected granulomatous disease, chronic, X-linked National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 2140 trials
Phase 2 NCT07562568 Background Jun 2026 → Jun 2030 expected acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome The First Affiliated Hospital of Soochow University Not yet recruiting No outcome recorded
Phase 2 NCT07575412 Background Jun 2026 → Jun 2029 expected acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome The First Affiliated Hospital of Soochow University Not yet recruiting No outcome recorded
Phase 2 NCT05617625 Background Jun 2026 → Jun 2033 graft versus host disease, myelodysplastic syndrome Guenther Koehne Suspended No outcome recorded
Phase 2 NCT07566377 Background Apr 2026 → Apr 2030 expected Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, graft versus host disease +1 Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 2 NCT07441967 Background Feb 2026 → Dec 2027 expected hematopoietic and lymphoid system neoplasm Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Show all 140 trials opens the full record — a long page
Phase 2/319 trials
Phase 2/3 NCT07052422 Background Jul 2025 → Dec 2027 expected myeloid neoplasm Nanfang Hospital, Southern Medical University Not yet recruiting No outcome recorded
Phase 2/3 NCT04123392 Background Oct 2019 → Sep 2022 myeloid neoplasm Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT04098653 Background Sep 2019 → Aug 2022 disease related to hematopoietic stem cell transplant, myeloid neoplasm Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT03799224 Background Dec 2018 → Dec 2021 acute leukemia, disease related to hematopoietic stem cell transplant Peking University People's Hospital Unknown No outcome recorded
Phase 2/3 NCT03793517 Background Sep 2018 → Oct 2023 overdue acute myeloid leukemia, disease related to hematopoietic stem cell transplant Peking University People's Hospital Recruiting No outcome recorded
Phase 330 trials
Phase 3 NCT06673459 Comparator Dec 2024 → Nov 2029 expected T-cell leukemia The First Affiliated Hospital of Soochow University Not yet recruiting No outcome recorded
Phase 3 NCT06297772 Background Jun 2024 → Mar 2026 overdue acute myeloid leukemia Ruijin Hospital Not yet recruiting No outcome recorded
Phase 3 NCT06079879 Comparator Dec 2023 → Jul 2027 expected essential thrombocythemia Merck Sharp & Dohme LLC Active not recruiting No outcome recorded
Phase 3 NCT05991908 Comparator Oct 2023 → Oct 2025 overdue acute myeloid leukemia, myelodysplastic syndrome Shanghai Jiao Tong University School of Medicine Recruiting No outcome recorded
Phase 3 NCT05907486 Background Aug 2023 → Aug 2025 thrombotic disease The First Affiliated Hospital of Soochow University Unknown No outcome recorded
Phase 43 trials
Phase 4 NCT04009525 Background Jul 2019 → Jul 2023 beta-thalassemia major First Affiliated Hospital of Guangxi Medical University Completed No outcome recorded
Phase 4 NCT03171831 Background Apr 2017 → Dec 2021 beta-thalassemia major First Affiliated Hospital of Guangxi Medical University Unknown No outcome recorded
Phase 4 NCT02784561 Background Jul 2016 → Jul 2019 leukemia Chinese PLA General Hospital Unknown No outcome recorded
Phase not applicable23 trials
NCT07563920 Background Jun 2026 → Jun 2029 expected acute myeloid leukemia Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
NCT07588360 Background Oct 2025 → Oct 2028 expected acute myeloid leukemia, myelodysplastic syndrome Fujian Medical University Union Hospital Recruiting No outcome recorded
NCT05667402 Background Jan 2023 → Dec 2025 central nervous system leukemia, disease related to hematopoietic stem cell transplant First Affiliated Hospital Xi'an Jiaotong University Unknown No outcome recorded
NCT02469974 Background May 2015 → Aug 2016 myelofibrosis Marina Kremyanskaya Withdrawn No outcome recorded
NCT01779882 Comparator Jan 2013 → Jan 2018 lymphoid neoplasm, myeloid leukemia University Hospital, Basel, Switzerland Completed No outcome recorded
Phase not stated1 trial
NCT00423826 Background Jan 2007 → Jan 2015 leukemia, myelodysplastic syndrome, myelofibrosis, plasma cell neoplasm +1 Barbara Ann Karmanos Cancer Institute No longer available No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2021-08-25 Otsuka Pharmaceutical Development & Commercialization, Inc. Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients otsuka.co.jp
2020-03-25 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma otsuka.co.jp
2018-09-25 Otsuka Pharmaceutical Development & Commercialization, Inc. Busulfex Injection 60mg Approved in Japan for Once-Daily Administration in Adults otsuka.co.jp
2012-09-14 Otsuka Pharmaceutical Development & Commercialization, Inc. Kyowa Hakko Kirin Returns to Otsuka Pharmaceutical the Rights to Develop and Market Busulfex, for Use As a Part of Conditioning Regimen Prior to Hematopoietic Progenitor Cell Transplantation, in Japan and in Asian Countries & Regions® otsuka.co.jp
2007-12-18 Otsuka Pharmaceutical Development & Commercialization, Inc. OTSUKA PHARMACEUTICAL ACQUIRES RIGHTS TO IV BUSULFEX FROM PDL BIOPHARMA otsuka.co.jp

Evidence & citations 26 cited values

Every value below carries the sentence it was read from. 611 sources stand behind the page.

FieldValueCited text
Known as Busulfan “RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4),...” NCT03412266
597

Busulfan Plus Cyclophosphamide Vs. Total Body Irradiation Plus Cyclophosphamide for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute T Lymphoblastic...” NCT06673459

“The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and...” NCT06468267

“Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4,...” NCT01435447

“The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem...” NCT01496547

“Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem...” NCT01049854

“Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3.” NCT00152113

“Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases” NCT02483325

“Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide” NCT02098512

“pentostatin 4 mg/m2/day IV on days -11 and -7, cyclophosphamide 3 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.” NCT02579967

“Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation” NCT05870995

Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML” NCT01191957

“Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide” NCT02766868

“Poor responders will undergo to stem cells apheresis and their reinfusion after treatment with high doses of Busulfan and Melphalan 25 weeks.” NCT02063022

“Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide.” NCT00145587

“Flu-Bu-ATG (Study A) associated Fludarabine (30mg/m²/5 days), Oral Busulfan (8 mg/kg over 2 days) and Thymoglobuline (2.5 mg/m²/1day).” NCT00894049

“intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4” NCT00774280

Busulfan/Cyclophosphamide, "standard" conditioning regimen as a control group. including Bu3.2mg/kg -5\~-3d; Cy 80mg/kg,-2\~-1d。” NCT06133556

“RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6)” NCT03412409

Busulfan injection: for patients under 55 years old with HCT-CI score of 2 or below, use 3.2mg/kg/d from -5d to -3d (3d)” NCT07276737

“reduced intensity conditioning regimen consisting of Fludarabine (150mg/m2) + Busulfan (6.4mg/kg) + Melphalan (70mg/m2)” NCT04904237

“high-dose rituximab combined with thiotepa, busulfan, and cyclophosphamide (R-TBC) for ASCT was conducted.” PMID 25204639 Sep 2014

“The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.” NCT05667402

Busulfan, a routine transplant chemotherapy will be given on days -5 to -2 as IV infusion.” NCT06315309

“Chemotherapies: busulfan, fludarabine, melphalan, cyclophosphamide, thiotepa, clofarabine” NCT04761770

Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days.” NCT00176826

Busulfan: 0.8 mg/kg intravenously every 6 hours on days -4 to -2 (total of 12 doses).” NCT07583888

“Oral or Intravenous Busulfan as part of the preparative protocol for transplantation” NCT01071486

“Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2” NCT04897139

“Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once;” NCT05075681

“Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.” NCT03509961

“Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan” NCT05436561

Busulfan, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF” NCT02053545

“receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning.” NCT01639690

“Fludarabine 150mg/m2 + Busulfan 3.2mg/kg 2 days + melphalan 50-70mg/m2” NCT04269811

Busulfan IV AUC targeted dose of 14.8-23.0 mg*h/L, on days -3 and -2.” NCT05470491

“IV Busulfan (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3)” NCT02333838

“Intravenous busulfan (Busulfan®) in combination with fludarabine” NCT00943319

Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4” NCT02084563

“130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)” NCT02876679

busulfan 0.8 mg/kg q6h on days -6,-5, -4 (total 3.2 mg/kg/day)” NCT07575412

“Myeloablative regimen of busulfan, fludarabine, and thiotepa.” NCT06900192

busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6” NCT03799224

busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6” NCT03793517

“ATG will be infused after fludarabine \& busulfan infusion.” NCT03456817

Busulfan IV, pharmacokinetically dosed, on days -3 and -2.” NCT03663933

Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5)” NCT00336843

Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)” NCT03035422

Busulfan, IV, D-5 to D-2, dosa according to the weight” NCT03011528

Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-4 and D-3” NCT01985061

Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2” NCT01860170

Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2” NCT00763490

“Busulfex (busulfan) - drug class: alkylating agent” NCT02626715

Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)” NCT03079089

busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9” NCT01461837

Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po” NCT01238328

“modified BUCY (busulfan and cyclophosphamide)” NCT05809167

“modified BUCY (busulfan and cyclophosphamide)” NCT05823714

Busulfan: 3.2 mg/kg IV daily on days -7 to -4” NCT01015742

busulfan (Bu) (3.2 mg/kg/day, days -8 to -6)” NCT06984536

Busulfan IV (0.8 mg/kg X 10) day-6 to day-4” NCT00863460

busulfan 130mg/m2/d for 2 days over 3 hours” NCT00597714

Busulfan, Carmustine, and Cyclophosphamide” NCT05425654

“Day -5 to Day -2: Busulfan and Fludaribine” NCT03314974

busulfan (3.2 mg/kg/day on days -8 to -6)” NCT07677306

busulfan 0.8 mg/kg q6h on days -5, -4, -3” NCT07562568

Busulfan 3.2 mg/kg/d from -7 to -5 days” NCT06816134

busulfan (0.8mg/kg, Q6h, days -8 to -6)” NCT04582604

“Chemotherapy conditioning with BusulfanNCT01129544

busulfan IV, pharmacokinetically dosed” NCT03922724

busulfan 3.2mg/kg/day on day -7 to -5;” NCT03256071

Busulfan 3.2 mg/kg/d i.v. d-7 and d-6” NCT06830421

busulfan 3.2 mg/kg/d on days -8,-7,-6” NCT07588594

Busulfan 3,2 mg/kg/d i.v. (d-8-(-7))” NCT02531841

“Day- 8 # Busulfan 0.8mg/ kg Q6h iv” NCT05088226

“Bortezomib, Busulfan, Carboplatin” NCT02788201

Busulfan(B) (IV)0.8mg/kg Q6hx2d” NCT03821987

“Bosutinib Busulfan Cabazitaxel” NCT02551718

Busulfan and Melfalan (BUMEL)” NCT02727387

“iv Busulfan (3.2mg/kg/d)” NCT06758726

Busulfan and fludarabine” NCT06859424

busulfan 3.2mg / kg-6d” NCT06769568

Busulfan: 3.2mg/m2/d” NCT05583175

Busulfan (BU)” NCT01565616

“* BusulfanNCT00167219

“* BusulfanNCT02179359

“* BusulfanNCT02171104

BusulfanNCT06385808

BusulfanNCT02629120

NCT00003336

NCT00458250

NCT00361140

NCT06207799

NCT00502905

NCT00536601

NCT03602131

NCT00691015

NCT00024050

NCT04872595

NCT00802113

NCT05564390

NCT03779854

NCT00156858

NCT00550992

NCT04547049

NCT00943319

NCT06851767

NCT00841724

NCT01457885

NCT01306019

NCT02627573

NCT00004181

NCT07441967

NCT03171831

NCT00006126

NCT01852071

NCT01961063

NCT06001385

NCT00317408

NCT02129582

NCT00750126

NCT00004907

NCT00077116

NCT02861417

NCT00619645

NCT02727803

NCT01413178

NCT00003662

NCT01629511

NCT00990249

NCT00863148

NCT06959771

NCT00003661

NCT03128359

NCT01749293

NCT00582933

NCT01505569

NCT01366612

NCT00186966

NCT01156350

NCT00281879

NCT00040469

NCT00436761

NCT00540995

NCT00025402

NCT00547196

NCT00357565

NCT00002789

NCT03733327

NCT00357396

NCT00555048

NCT01464359

NCT05991908

NCT00881556

NCT06506461

NCT00874315

NCT00002792

NCT05598593

NCT00025649

NCT03121014

NCT01200329

NCT00003414

NCT03229616

NCT00004171

NCT00705120

NCT00004088

NCT00070174

NCT00556452

NCT03794167

NCT05449899

NCT00070135

NCT00887042

NCT05565105

NCT00238433

NCT00002798

NCT00802568

NCT00787761

NCT01779882

NCT00836628

NCT04644016

NCT03018223

NCT00002701

NCT01181271

NCT00417053

NCT00002961

NCT00521430

NCT00801931

NCT05453552

NCT00410982

NCT00818961

NCT00578344

NCT00623077

NCT00003081

NCT00667927

NCT03096782

NCT04098393

NCT02506959

NCT01572181

NCT04098653

NCT00228852

NCT00668564

NCT03259503

NCT03126916

NCT03240861

NCT00454480

NCT01857934

NCT03385096

NCT02047578

NCT01018446

NCT00003816

NCT01596699

NCT02859402

NCT05457556

NCT00027924

NCT01572662

NCT00093587

NCT00027937

NCT02589145

NCT01421173

NCT07014943

NCT06325709

NCT01274195

NCT00941720

NCT04904588

NCT00003270

NCT00265889

NCT00295997

NCT03615105

NCT03384225

NCT00498316

NCT02793544

NCT02582775

NCT00004231

NCT03384212

NCT00003146

NCT00296023

NCT06252870

NCT00014469

NCT00290628

NCT01390402

NCT03596892

NCT07113743

NCT00081055

NCT00005866

NCT01499147

NCT05463133

NCT02836639

NCT00795132

NCT00943800

NCT07085156

NCT03530085

NCT07052422

NCT00623935

NCT02061800

NCT06809712

NCT01056614

NCT00020566

NCT05617625

NCT00002771

NCT00806767

NCT00208923

NCT01959477

NCT00003875

NCT01093586

NCT00024193

NCT00469014

NCT00003619

NCT01027000

NCT00669890

NCT00531310

NCT04945096

NCT03674411

NCT05327023

NCT03653247

NCT06809699

NCT01701986

NCT01020539

NCT06802315

NCT04384692

NCT01050855

NCT05466318

NCT00615589

NCT00005940

NCT00469144

NCT01916252

NCT02577094

NCT00638820

NCT00002547

NCT02083250

NCT05807659

NCT03517631

NCT00112645

NCT00004899

NCT00402558

NCT00002831

NCT00043810

NCT00313625

NCT04339777

NCT00152126

NCT01044745

NCT00002768

NCT06872333

NCT00416598

NCT02472392

NCT00997386

NCT01020734

NCT00002549

NCT01019876

NCT03579875

NCT01949129

NCT04220008

NCT00578643

NCT00305708

NCT03619551

NCT00544115

NCT00630565

NCT01203020

NCT02310997

NCT00423826

NCT01746173

NCT03303950

NCT01247701

NCT00475020

NCT05027945

NCT00813124

NCT01798004

NCT01498016

NCT07566377

NCT01410344

NCT01279616

NCT02916979

NCT06337331

NCT00670410

NCT00002554

NCT02670252

NCT00885833

NCT00679536

NCT00245037

NCT05170828

NCT03597594

NCT02251821

NCT00005986

NCT01063439

NCT02766465

NCT02057770

NCT05735717

NCT00007995

NCT00005797

NCT01702831

NCT00800839

NCT01471444

NCT02248597

NCT04370795

NCT01384513

NCT04451200

NCT00176930

NCT00627666

NCT00176917

NCT02724163

NCT00176904

NCT00322101

NCT00176878

NCT01359254

NCT04942730

NCT07565220

NCT00003913

NCT00516152

NCT01773395

NCT00003926

NCT02130869

NCT00176852

NCT05674539

NCT00334672

NCT01512888

NCT00176839

NCT01760655

NCT05579769

NCT01643668

NCT00328029

NCT03602898

NCT01969942

NCT00258427

NCT02143830

NCT04713956

NCT00950846

NCT04009525

NCT02250937

NCT00004896

NCT02671708

NCT00134017

NCT00822393

NCT01685411

NCT00513474

NCT04688021

NCT03247088

NCT00060255

NCT01786018

NCT00003060

NCT00003101

NCT02784561

NCT00003335

NCT00006246

NCT02007863

NCT01119066

NCT02750254

NCT00796562

NCT00613561

NCT00029380

NCT03538899

NCT02799147

NCT00987480

NCT00186810

NCT00346359

NCT00588523

NCT03515707

NCT02512497

NCT05569512

NCT04690192

NCT03795597

NCT01455506

NCT05917405

NCT00030719

NCT00002502

NCT00008190

NCT00598481

NCT01500161

NCT02469974

NCT00408447

NCT03339700

NCT03600909

NCT01625351

NCT00427765

NCT00948090

NCT03613532

NCT01824693

NCT02605460

NCT01704716

NCT00822770

NCT01178658

NCT01175356

NCT02410551

NCT01178645

NCT00084695

NCT01349101

NCT01135329

NCT01605032

NCT00049517

NCT00113919

NCT00506857

NCT02701673

NCT00002761

NCT01707004

NCT05293509

NCT00006367

NCT06069180

NCT06158828

NCT02500849

NCT02034630

NCT06079879

NCT00245115

NCT00987636

NCT01471067

NCT00934232

NCT03983850

NCT05477589

NCT03792815

NCT02544425

NCT04282174

NCT01795430

NCT02282904

NCT01048827

NCT00445744

NCT01861106

NCT03151876

NCT04151706

NCT07563920

NCT00006056

NCT00304018

NCT00005948

NCT02441803

NCT06996119

NCT04708054

NCT00857389

NCT00809276

NCT01033552

NCT00049634

NCT01983969

NCT00003462

NCT03765632

NCT04982354

NCT00534469

NCT04127721

NCT00775931

NCT00006054

NCT03235973

NCT00446173

NCT00612716

NCT00003960

NCT01237951

NCT03970096

NCT00004128

NCT00578292

NCT00253487

NCT00055653

NCT01338675

NCT00003972

NCT01087398

NCT00534430

NCT00002868

NCT03315078

NCT00638898

NCT01983761

NCT02294552

NCT00281983

NCT01009840

NCT00301834

NCT02670109

NCT00426517

NCT05303727

NCT01118013

NCT00003195

NCT01666080

NCT01758328

NCT01177371

NCT00054340

NCT00301912

NCT00054327

NCT01338987

NCT00006363

NCT03910452

NCT01652092

NCT00092937

NCT05907486

NCT00238368

NCT00301951

NCT01380990

NCT00005824

NCT02806375

NCT01734850

NCT00782379

NCT06247917

NCT07524530

NCT00804947

NCT00815568

NCT00005641

NCT00611351

NCT02961816

NCT01622556

NCT06869265

NCT00363467

NCT02660281

NCT00005893

NCT02744742

NCT00002592

NCT06613035

NCT04123392

NCT06345495

NCT01043640

NCT00448201

NCT01621477

NCT07588360

NCT00478244

NCT00553202

NCT00002989

NCT00448357

NCT01823198

NCT01003054

NCT00579111

NCT01534143

NCT01131169

NCT02114502

NCT00852163

NCT06297772

NCT00053196

NCT04002115

NCT00003116

NCT00496340

NCT00499889

NCT00684255

NCT00840684

NCT00003199

NCT02120157

NCT07228624

NCT01168219

NCT04221035

NCT00253552

NCT00034528

NCT07644481

NCT01427881

NCT00629798

NCT01339910

NCT00740467

NCT04859946

NCT01071239

NCT04776850

NCT01176006

NCT01339988

NCT02999984

Known as 1, 4-Bis[methanesulfonoxy]butane 1, 4-Bis[methanesulfonoxy]butaneNCT01168219
Known as bulsulfan “conditioning regimen before autologous stem cell transplantation consists of thiotepa, bulsulfan, and cyclophosphamide from day -9.” NCT06625359
Known as Busilvex “Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases” NCT02483325
7

“Conventional conditioning regimen with intravenous (i.v.) Busulphan (Busilvex), 12.8 mg/kg followed by Cyclophosphamide, 120 mg/kg iv.” NCT01191957

“IV Busulfan IV (Busilvex®) - Anti-thymocyte globulines” NCT01572181

“Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-4 and D-3” NCT01985061

“Drug: busulfan (Busilvex ®)” NCT01916252

“Busulphan (Busilvex)” NCT01814475

NCT02349906

NCT02025881

Known as busulfan (BSF) busulfan (BSF)NCT01707004
Known as busulfan (BU) busulfan (BU)NCT01707004
1

Busulfan (BU)NCT01565616

Known as Busulfan (Busulfex), “Busulfan (Busulfex®),” NCT00997386
Known as Busulfan fresenius kabi ChEMBL registry synonym — accepted as the source's own label CHEMBL820
Known as Busulfano ChEMBL registry synonym — accepted as the source's own label CHEMBL820
Known as Busulfanum ChEMBL registry synonym — accepted as the source's own label CHEMBL820
Known as Busulfex “intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4” NCT00774280
11

Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2” NCT01751997

“intravenous busulfan (busulfex®)” NCT00582933

“4 doses of IV BusulfexNCT00531310

“Busulfan (Busulfex)” NCT01176006

“Busulfan (Busulfex)” NCT01861106

“Busulfan (Busulfex)” NCT06809699

“Busulfan (Busulfex)” NCT06809712

NCT00582894

NCT00153985

NCT01923935

NCT00282282

Known as Busulphan “''Busulphan'' will be used in place of ''TBI'' in equivalent myelotoxic dose to facilitate engraftment” NCT03955601
5

NCT01814475

NCT00916045

NCT00915811

NCT01191957

NCT04217278

Known as iv-Bu “Intravenous Busulfan (iv-Bu) is commonly used as part of preparation regimen for allogeneic hematopoietic stem cell transplantation for patients with acute leukemia.” NCT01498016
1

“the condition with iv-busulfan (iv-BU) and cyclophosphamide (CTX) is feasible with low toxicity” NCT01435447

Known as Leucosulfan ChEMBL registry synonym — accepted as the source's own label CHEMBL820
Known as Myelosan ChEMBL registry synonym — accepted as the source's own label CHEMBL820
Known as Myelosanum ChEMBL registry synonym — accepted as the source's own label CHEMBL820
Known as Myleran ChEMBL registry synonym — accepted as the source's own label CHEMBL820
Known as NCI-C01592 ChEMBL registry synonym — accepted as the source's own label CHEMBL820
Known as NSC-750 “Iodine-131-labeled Monoclonal Antibody BC8 (anti-CD45), 131I-BC8; plus Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, ABM; with,...” NCT00002554
1

“Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, AlBM; with, as indicated, Intrathecal Cytarabine, IT ARA-C, NSC-63878.” NCT00002502

Known as Spartaject-Busulfan “Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis” NCT00006246
Known as Sulphabutin ChEMBL registry synonym — accepted as the source's own label CHEMBL820
Known as Tetramethylene bis[methanesulfonate] Tetramethylene bis[methanesulfonate]NCT02727803
Known as ◦Drug: Busulfan ◦Drug: BusulfanNCT01983761
Action Deplete “busulfan, a drug that targets myeloid cells, killing them” NCT00092937
Modality Small molecule “Busulfan and melphalan are both traditional alkylating agents” NCT00427765